Compare Crispr Therapeutics AG (CRSP) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Estee Lauder Companies Inc — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Estee Lauder Companies Inc trades at $81.04 (market cap $29.25B). The key difference: Estee Lauder Companies Inc is far larger — about 5.9× Crispr Therapeutics AG's market cap, and Estee Lauder Companies Inc pays a 1.73% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | EL | |
|---|---|---|
Market Cap | $4.97B | $29.25B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $119.61 |
52-Week Low | $44.34 | $67.23 |
Enterprise Value | $3.32B | $35.43B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Estée Lauder (EL) trades at $81.15, down 1.83% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows negative net income and declining revenue trends, though recent quarters have beaten EPS estimates. Analyst consensus is divided with a $90.60 price target, while technical indicators point to support near $80.
Outlook remains cautious due to profitability challenges and competitive pressures, but potential upside exists if cost controls and innovation drive margin recovery. Key risks include sustained earnings pressure and macroeconomic sensitivity in the beauty sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
